William G. Wierda, MD, PhD, Nicole Lamanna, MD - Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents and Innovative Combinations episode artwork

EPISODE · Oct 6, 2023 · 1H 1M

William G. Wierda, MD, PhD, Nicole Lamanna, MD - Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents and Innovative Combinations

from PeerView Clinical Pharmacology CME/CNE/CPE Video · host PVI, PeerView Institute for Medical Education

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Episode metadata supplied by the publisher feed · Published Oct 6, 2023

Embed this episode

Ready to play

William G. Wierda, MD, PhD, Nicole Lamanna, MD - Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents and Innovative Combinations

0:00 1:01:53

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of PeerView Clinical Pharmacology CME/CNE/CPE Video?

This episode is 1 hour and 1 minute long.

When was this PeerView Clinical Pharmacology CME/CNE/CPE Video episode published?

This episode was published on October 6, 2023.

Can I download this PeerView Clinical Pharmacology CME/CNE/CPE Video episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!